17:48-6K

LEGISLATIVE HISTORY CHECKLIST

Compiled by the NJ State Law Library

(Health benefits--insurance--

cancer)

NJSA:

17:48-6K

LAWS OF:

1995

CHAPTER:

100

BILL NO:

A1997

SPONSOR(S):

Cohen and others

DATE INTRODUCED:

August 15, 1994

COMMITTEE:

ASSEMBLY:

Insurance; Health & Human Services

SENATE:

Health

AMENDED DURING PASSAGE:

Yes

Amendments during passage

denoted by superscript numbers

DATE OF PASSAGE:

ASSEMBLY:

February 6, 1995

SENATE:

March 30, 1995

DATE OF APPROVAL:

May 9, 1995

FOLLOWING STATEMENTS ARE ATTACHED IF AVAILABLE:

SPONSOR STATEMENT:

Yes

COMMITTEE STATEMENT:

ASSEMBLY:

Yes 1-19-95 & 12-12-94

SENATE:

Yes

FISCAL NOTE:

No

VETO MESSAGE:

No

MESSAGE ON SIGNING:

No

FOLLOWING WERE PRINTED:

REPORTS:

No

HEARINGS:

No

See newspaper clippings--attached:

"New law required insurers to offer bone marros transplant coverage," 5-10-95, Star Ledger.

"New laws address health & safety," 5-10-95, Asbury Park Press.

KBG:pp

[FIRST REPRINT] ASSEMBLY, No. 1997

STATE OF NEW JERSEY

INTRODUCED AUGUST 15, 1994

By Assemblymen COHEN, COLBURN, Moran, Suliga, Jones, Lustbader, Charles, Assemblywoman Quigley, Assemblymen Augustine, Russo, Assemblywomen Ogden, Gregory-Scocchi, Assemblymen Kavanaugh, Felice, Assemblywoman Gill, Assemblymen DiGaetallo, Doria, Impreveduto, Dalton, Assemblywoman Turner, Assemblymen Romano, Oros, Lance, Assemblywoman Haines, Assemblymen Warsh, Petrillo, Foley, Catania, Zecker, Kelly, Williams, Assemblywoman Murphy, Assemblyman Pascrell, Assemblywoman Weinberg, Assemblymen Zisa, Roberts, Yuhas, Corodemus, Assemblywoman J. Smith, Assemblymen Solomon, Mikulak, Collins, Assemblywoman Vandervalk, Assemblymen Kramer, Roma, Rooney, Assemblywoman Heck and Assemblyman Bateman

AN ACT ¹concerning health insurance and ¹ requiring health insurers to offer benefits for certain treatments of cancer under certain conditions and supplementing P.L.1938, c.366 (C.17:48-1 et seq.), P.L.1940, c.74 (C.17:48A-1 et seq.), P.L.1985, c.236 (C.17:48E-1 et seq.), chapters 26 and 27 of Title 17B of the New Jersey Statutes and P.L.1973, c.337 (C.26:2J-1 et seq.).

7 8 9

10

11

12

13 14

15

16 17

18

19

20

21

22 23

2425

26

27

28

29

30 31

32

33

34

35

1

2

3 4

5

6

BE IT ENACTED by the Senate and General Assembly of the State of New Jersey:

1.1[Except as otherwise] (New section) In addition to benefits1 provided ¹[in] <u>under regulations adopted pursuant to 1 P.L.1992</u>, c.161 (C.17B:27A-2 et seq.) and P.L.1992, c.162 (C.17B:27A-17 et seq.), a hospital service corporation shall offer under every group or individual hospital service corporation contract providing hospital or medical expense benefits delivered, issued, executed or renewed in this State, or approved for issuance or renewal in this State by the Commissioner of Insurance, on or after the effective date of this act to provide benefits for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants ¹[or] and peripheral blood ¹ stem cell transplants when performed ¹[pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced in dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants] by institutions approved by the National Cancer Institute or pursuant to protocols consistent with the guidelines of the American Society of Clinical Oncologists¹. Benefits for such treatment shall be provided to the same extent as for any other illness under the contract. ¹[No preexisting condition exclusion shall apply to such benefits.]1

The offer required pursuant to this section shall apply to all hospital service corporation contracts in which the hospital

EXPLANATION--Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted in the law.

2

1 2

3 4

5

6 7

8

9

10

11 12

13 14

15

16

17

18

19

20 21

2223

24

2526

27

28

29 30

31

32

33 34

35

36 37

38

39 **40**

41

42

43

44

45

46

47

48

49 50

51 52

53

54

service corporation has reserved the right to change the premium. ¹Nothing in this section shall be construed to limit a hospital service corporation in adjusting premium amounts, or providing for reasonable deductibles or copayments, with respect to benefits provided pursuant to this section. ¹

2.1[Except as otherwise] (New section) In addition to benefits1 provided ¹[in] <u>under regulations adopted pursuant to</u> ¹ P.L.1992, c.161 (C.17B:27A-2 et seq.) and P.L.1992, c.162 (C.17B:27A-17 et seq.), a medical service corporation shall offer under every group or individual medical service corporation contract providing hospital or medical expense benefits delivered, issued, executed or renewed in this State, or approved for issuance or renewal in this State by the Commissioner of Insurance, on or after the effective date of this act to provide benefits for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants ¹[or] and peripheral blood ¹ stem cell transplants when performed ¹[pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced in dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants] by institutions approved by the National Cancer Institute or pursuant to protocols consistent with the guidelines of the American Society of Clinical Oncologists¹. Benefits for such treatment shall be provided to the same extent as for any other illness under the contract. ¹[No preexisting condition exclusion shall apply to such benefits.]1

The offer required pursuant to this section shall apply to all medical service corporation contracts in which the medical service corporation has reserved the right to change the premium.

Nothing in this section shall be construed to limit a medical service corporation in adjusting premium amounts, or providing for reasonable deductibles or copayments, with respect to benefits provided pursuant to this section.

1

3.1[Except as otherwise] (New section) In addition to benefits1 provided ¹[in] <u>under regulations adopted pursuant to ¹ P.L.1992</u>, c.161 (C.17B:27A-2 et seq.) and P.L.1992, c.162 (C.17B:27A-17 et seq.), a health service corporation shall offer under every group or individual health service corporation contract providing hospital or medical expense benefits delivered, issued, executed or renewed in this State, or approved for issuance or renewal in this State by the Commissioner of Insurance, on or after the effective date of this act to provide benefits for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants ¹[or] and peripheral blood ¹ stem cell transplants when performed ¹[pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced in dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants] by institutions approved by the National Cancer Institute or pursuant to protocols consistent with the guidelines of the American Society

3

of Clinical Oncologists¹. Benefits for such treatment shall be provided to the same extent as for any other illness under the contract. ¹[No preexisting condition exclusion shall apply to such benefits.]¹

5 6

7

8 9

10

11 12

13

14

15

16

17 18

19

20

2122

23

24

25

26

27

28 29

30

31

32 33

34

35

36

37

38

39 40

41

42

43

44

45 46

47

48

49

50 51

52 53

54

The offer required pursuant to this section shall apply to all health service corporation contracts in which the health service corporation has reserved the right to change the premium.

1 Nothing in this section shall be construed to limit a health service corporation in adjusting premium amounts, or providing for reasonable deductibles or copayments, with respect to benefits provided pursuant to this section. 1

4.1 [Except as otherwise] (New section) In addition to benefits1 provided ¹[in] <u>under regulations adopted pursuant to 1 P.L.1992</u>, c.161 (C.17B:27A-2 et seq.)¹, 1 an insurer shall offer under every individual policy providing health insurance coverage delivered, issued, executed or renewed in this State, or approved for issuance or renewal in this State by the Commissioner of Insurance, on or after the effective date of this act to provide benefits for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants ¹[or] and peripheral blood 1 stem cell transplants when performed ¹[pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants] by institutions approved by the National Cancer Institute or pursuant to protocols consistent with the guidelines of the American Society of Clinical Oncologists¹. Benefits for such treatment shall be provided to the same extent as for any other illness under the policy. ¹[No preexisting condition exclusion shall apply to such benefits.]1

The offer required pursuant to this section shall apply to all health insurance policies in which the insurer has reserved the right to change the premium.

1 Nothing in this section shall be construed to limit an insurer in adjusting premium amounts, or providing for reasonable deductibles or copayments, with respect to benefits provided pursuant to this section.

5.1[Except as otherwise] (New section) In addition to benefits1 provided ¹[in] under regulations adopted pursuant to ¹ P.L.1992, c.162 (C.17B:27A-17 et seq.), an insurer shall offer under every group policy providing health insurance coverage delivered, issued, executed or renewed in this State, or approved for issuance or renewal in this State by the Commissioner of Insurance on or after the effective date of this act to provide benefits for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants ¹[or] and peripheral blood 1 stem cell transplants when performed ¹[pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced dose-intensive chemotherapy/autologous bone transplants or stem cell transplants] by institutions approved by

the National Cancer Institute or pursuant to protocols consistent with the guidelines of the American Society of Clinical Oncologists¹. Benefits for such treatment shall be provided to the same extent as for any other illness under the policy. ¹[No preexisting condition exclusion shall apply to such benefits.]¹

The offer required pursuant to this section shall apply to all health insurance policies in which the insurer has reserved the right to change the premium.

1 Nothing in this section shall be construed to limit an insurer in adjusting premium amounts, or providing for reasonable deductibles or copayments, with respect to benefits provided pursuant to this section.

6.1[Except as otherwise] (New section) In addition to benefits1 provided ¹[in] <u>under regulations adopted pursuant to</u> ¹ P.L.1992, c.161 (C.17B:27A-2 et seq.) and P.L.1992, c.162 (C.17B:27A-17 et seq.), no certificate of authority to establish and operate a health maintenance organization in this State shall be issued or continued on or after the effective date of this act unless the health maintenance organization offers to provide health care services to any ¹[enrollee] contract holder¹ for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants ¹[or] and peripheral blood¹ stem cell transplants when performed ¹[pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced in dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants] by institutions approved by the National Cancer Institute or pursuant to protocols consistent with the guidelines of the American Society of Clinical Oncologists 1. This treatment shall be provided to the same extent as for any other illness. ¹[No preexisting condition exclusion shall apply to such benefits.]¹

The offer required pursuant to this section shall apply to all contracts for health care services by health maintenance organizations under which the right to change the schedule of charges for enrollee coverage is reserved.

1 Nothing in this section shall be construed to limit a health maintenance organization in adjusting the schedule of charges for enrollee coverage, or providing for reasonable deductibles or copayments, with respect to benefits provided pursuant to this section.

¹7. (New section) a. Nothing in this act shall be construed to diminish any current or future health care benefits contract in this State.

 1 [7.] $8.^{1}$ This act shall take effect on the 90th day after enactment.

5

Requires health insurers to offer to provide benefits for dose-intensive chemotherapy/autologous bone marrow transplants and peripheral blood stem cell transplants under certain conditions.

shall be provided to the same extent as for any other illness under the policy. No preexisting condition exclusion shall apply to such benefits.

The offer required pursuant to this section shall apply to all health insurance policies in which the insurer has reserved the right to change the premium.

Except as otherwise provided in P.L.1992, (C.17B:27A-17 et seq.), an insurer shall offer under every group policy providing health insurance coverage delivered, issued, executed or renewed in this State, or approved for issuance or renewal in this State by the Commissioner of Insurance on or after the effective date of this act to provide benefits for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants when performed pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced dose-intensive chemotherapy/autologous bone transplants or stem cell transplants. Benefits for such treatment shall be provided to the same extent as for any other illness under the policy. No preexisting condition exclusion shall apply to such benefits.

The offer required pursuant to this section shall apply to all health insurance policies in which the insurer has reserved the right to change the premium.

Except as otherwise provided in P.L.1992, (C.17B:27A-2 et seq.) and P.L.1992, c.162 (C.17B:27A-17 et seq.), no certificate of authority to establish and operate a health maintenance organization in this State shall be issued or continued on or after the effective date of this act unless the health maintenance organization offers to provide health care services to any enrollee for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants when performed pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced in dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants. This treatment shall be provided to the same extent as for any other illness. No preexisting condition exclusion shall apply to such benefits.

The offer required pursuant to this section shall apply to all contracts for health care services by health maintenance organizations under which the right to change the schedule of charges for enrollee coverage is reserved.

7. This act shall take effect on the 90th day after enactment.

49 50

4

5

6 7

8

9

10 11

12 13

14

15

16

17

18 19

20

21

22

23

24

25

26

27

28

29

30

31 32

33 34

35 36

37 38

39

40 41

42 43

44

45 46

47

48

STATEMENT

51 52 53

54

This bill requires hospital service corporations, medical service corporations, health service corporations, commercial insurers

A1997

and health maintenance organizations to offer to provide coverage for the treatment of cancer by dose-intensive $% \left(1\right) =\left(1\right) \left(1\right$ chemotherapy/autologous bone marrow transplants or stem cell transplants when performed pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized hematologists or oncologists experienced in dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants. The bill prohibits the application of preexisting condition exclusions to such benefits.

Requires health insurers to offer to provide benefits for treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants under certain conditions.

ASSEMBLY HEALTH AND HUMAN SERVICES COMMITTEE

STATEMENT TO

ASSEMBLY, No. 1997 STATE OF NEW JERSEY

DATED: DECEMBER 12, 1994

The Assembly Health and Human Resources Committee favorably reports Assembly Bill No. 1997.

This bill requires hospital service corporations, medical service corporations, health service corporations, commercial insurers and health maintenance organizations to offer to provide coverage for treatment of cancer dose-intensive by chemotherapy/autologous bone marrow transplants or stem cell transplants when performed pursuant to protocols approved by the institutional review board of any United States medical teaching college including, but not limited to, National Cancer Institute protocols favorably reviewed and utilized by hematologists or oncologists experienced in dose-intensive chemotherapy/autologous bone marrow transplants or stem cell transplants. The bill prohibits the application of preexisting condition exclusions to such benefits.

This bill is identical to Senate Bill No. 1320 (Sinagra/Matheussen), which is currently pending in the Senate Health Committee.

ASSEMBLY INSURANCE COMMITTEE

STATEMENT TO

[FIRST REPRINT] ASSEMBLY, No. 1997

STATE OF NEW JERSEY

DATED: JANUARY 19, 1995

The Assembly Insurance Committee reports favorably Assembly Bill No. 1997 [1R].

This bill requires health insurers, including hospital service corporations, medical service corporations, health maintenance corporations, commercial insurers and health organizations, to offer to provide coverage for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants peripheral or stem cell transplants when performed by institutions approved by the National Cancer Institute or pursuant to protocols consistent with the guidelines of the American Society of Clinical Oncologists. A health insurer that provides benefits for such treatment as a part of its benefits package complies with the requirements of the bill.

The bill stipulates that the provisions of the bill shall not be construed to limit a health insurer's ability to adjust its premium amounts or schedule of charges, as appropriate, or to provide for reasonable deductibles or copayments, with respect to benefits pursuant to the bill.

The bill further provides that nothing in the bill shall be construed to diminish any current or future health care benefits contract in this State.

SENATE HEALTH COMMITTEE

STATEMENT TO

[FIRST REPRINT]
ASSEMBLY, No. 1997

STATE OF NEW JERSEY

DATED: FEBRUARY 27, 1995

The Senate Health Committee favorably reports Assembly Bill No. 1997 (1R).

This bill requires hospital service corporations, medical service corporations, health service corporations, commercial insurers and health maintenance organizations to offer to provide coverage for the treatment of cancer by dose-intensive chemotherapy/autologous bone marrow transplants and peripheral blood stem cell transplants when performed by institutions approved by the National Cancer Institute or pursuant to protocols consistent with the guidelines of the American Society of Clinical Oncologists. The bill specifies that nothing in the bill shall be construed to limit an insurer in adjusting premium amounts, or providing for reasonable deductibles or copayments, with respect to benefits provided under the bill.

The bill further provides that nothing in the bill shall be construed to diminish any current or future health care benefits contract in this State.

This bill is identical to Senate, No. 1320 (SCA) (Sinagra/Matheussen), which the committee also reported favorably on this date.